On Wednesday, Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $53.76 which represents a slight increase of $0.86 or 1.63% from the prior close of $52.9. The stock opened at ...

A Relative Strength Rating upgrade for Bristol Myers Squibb shows improving technical performance. Will it continue?

Dividend investing can create substantial passive income over time. A conservative example illustrates this potential: ...

Prime Medicine, Inc. has recently entered into a strategic research collaboration and license agreement with Bristol Myers Squibb (BMS) to develop and commercialize multiple prime edited ex vivo ...

Health Care Select Sector SPDR Fund ETF (XLV) outperformed the S&P 500 in Q3 2024. Bristol-Myers led growth while Moderna ...

You’ve likely heard that penny stocks are high-risk investments, and if so, you’ve heard right. However, a significant part ...

IGM Biosciences shifts focus to autoimmune diseases, reduces oncology research, and appoints former Bristol Myers Squibb ...

Dividend investing has become increasingly popular over time, as generating regular income remains a key focus for investors.

Leerink Partners analyst David Risinger has maintained their neutral stance on BMY stock, giving a Hold rating on September 26. David Risinger ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

In the year’s fourth-largest deal, Prime Medicine Inc. will collaborate with Bristol Myers Squibb Co. (BMS) in a research collaboration and license agreement totaling $3.61 billion. The two companies ...

Prime Medicine (PRME) shares rallied 15% Monday after the company announced a collaboration with Bristol Myers (BMY), which ...